Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Reuben Benjamin, Charlotte Graham, Deborah Yallop, +135

The Lancet

Hematological MalignancyCell TherapyTransplantationMedicineHematology +7

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, +47

New England Journal of Medicine

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Marie-Émilie Dourthe, Florence Rabian, Karima Yakouben, +25

Leukemia

Hematological MalignancyLymphoid NeoplasiaTransplantationMedicineMixed-phenotype Acute Leukemia +8

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Nitin Jain, Marcela V. Maus, +92

The Lancet Haematology

Hematological MalignancyLymphoid NeoplasiaCell TherapyMedicineImmunology +8

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay, Pedro Castro, Adel Maamar, +73

The Lancet Haematology

Clinical ImmunologyTranslational MedicineCell TherapyAutoimmune DiseaseAcute Care +6

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

Maximilian Stahl, Rory M. Shallis, Wei Wei, +32

Leukemia

Hematological MalignancyMedicineAcute Myeloid LeukemiaLong-term Clinical OutcomesHematology +7

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis

Marco Cerrano, Sylvie Chevret, Emmanuel Raffoux, +10

Annals of Hematology

Propensity ScoreHematological MalignancyMixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaMalignant Blood Disorder +6

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse

Sylvain Pilorge, Sophie Rigaudeau, Florence Rabian, +12

American Journal of Hematology

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

Marco Cerrano, Matthieu Duchmann, Rathana Kim, +24

Leukemia

Hematological MalignancyClonal DominanceMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia +11

The use of ICU resources in CAR-T cell recipients: a hospital-wide study

Sandrine Valade, Michaël Darmon, Lara Zafrani, +16

Annals of Intensive Care